Comparative costs of gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of non-small cell lung cancer in Germany

被引：0
|
作者：
Bischoff, H
Hamann, M
Stynes, G
Bhalla, S
Tilden, D
Kielhorn, A
机构：
[1] Stabsstelle Med Management, Heidelberg, Germany
[2] Eli Lilly Germany, Bad Homburg, Germany
[3] M TAG Ltd, Hammersmith, England
[4] Eli Lilly, Windlesham, Surrey, England
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)65750-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：674 / 674
页数：1
相关论文
共 50 条
  • [1] Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy
    Novello, S
    Kielhorn, A
    Stynes, G
    Selvaggi, G
    De Marinis, F
    Maestri, A
    Foggi, P
    Tilden, D
    Tonato, M
    Crinò, L
    Rinaldi, M
    Migliorino, AM
    Scagliotti, GV
    LUNG CANCER, 2005, 48 (03) : 379 - 387
  • [2] Comparison of quality of life of patients on treatment with cisplatin and gemcitabine, carboplatin and gemcitabine, carboplatin and paclitaxel, carboplatin and pemetrexed for non-small cell lung cancer
    Saranya, K.
    Sreejith, K.
    Ajaykumar
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (08) : 1853 - 1859
  • [3] Comparison of gemcitabine/carboplatin versus paclitaxel/cisplatin for the management of non-small cell lung cancer
    Wang, Wei
    Li, Wenli
    Dai, Lili
    Zhao, Lei
    Qu, Kaixin
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2022, 21 (08) : 1763 - 1770
  • [4] Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer
    J. R. Kroep
    E. F. Smit
    G. Giaccone
    K. Van der Born
    J. H. Beijnen
    C. J. Van Groeningen
    W. J. F. Van der Vijgh
    P. E. Postmus
    H. M. Pinedo
    G. J. Peters
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 509 - 516
  • [5] Gemcitabine/vinorelbine/cisplatin in patients with advanced non-small cell lung cancer
    Doweik, L
    Pohl, G
    Malayeri, R
    Krajnik, G
    Minar, W
    Pirker, R
    8TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2002, : 263 - 266
  • [6] Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer
    Comella, P
    SEMINARS IN ONCOLOGY, 2001, 28 (02) : 7 - 10
  • [7] Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer
    Hasturk, S
    Hatabay, N
    Ece, F
    Karatas, M
    Hanta, I
    LUNG CANCER, 2005, 49 : S247 - S247
  • [8] Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
    Ozkaya, Sevket
    Findik, Serhat
    Uzun, Oguz
    Atici, Atilla Guven
    Erkan, Levent
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2008, 2
  • [9] Sequential combination chemotherapy for advanced non-small cell lung cancer: Paclitaxel and cisplatin followed by vinorelbine and cisplatin
    Kim, H
    Kwon, J
    Jung, J
    Kim, J
    Song, H
    Lee, K
    Zang, D
    Ahn, J
    Lee, J
    Park, Y
    LUNG CANCER, 2005, 49 : S253 - S253
  • [10] Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC).
    Zhang, Y
    Zhang, L
    Li, N
    Xu, F
    Pan, ZK
    Guang, ZZ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
12345